The understanding of the structure and function of the DMD gene has given us neuromuscular specialists, children with dystrophy and their families endless hope. Unfortunately, these hopes are only a distant fairy tale at the moment. But we still believe that these stories will become reality. I introduced PTC, a drug for myotonic dystrophy, on my website a long time ago, and many patients have often approached me with hopes and inquiries about the results of the PTC Phase 3 clinical trial. The following is a report on the American herbal medicine source related to the PTC drug trial for your reference. In my opinion, gene therapy for myotonic dystrophy is still a long, long way to go. How to delay the skeletal muscle pathological changes, delay the life span of the affected children, and improve the quality of life of the affected children are the actual clinical topics facing our neuromuscular disease specialists and the current situation of treating DMD. We hope that more physicians will not wait for fairy tales, but take the clinical problems faced by each patient seriously and improve the quality of life by early diagnosis and reasonable interventions, including mitigation of skeletal muscle necrosis, abnormal interstitial hyperplasia, skeletal muscle contracture, and joint deformation.